PMID- 19847624
OWN - NLM
STAT- MEDLINE
DCOM- 20100813
LR  - 20211020
IS  - 1573-742X (Electronic)
IS  - 0929-5305 (Linking)
VI  - 29
IP  - 4
DP  - 2010 May
TI  - Hospital-based costs associated with venous thromboembolism prophylaxis regimens.
PG  - 449-58
LID - 10.1007/s11239-009-0371-x [doi]
AB  - Clinically and economically, venous thromboembolic (VTE) disease represents a 
      significant burden to the US healthcare system. This analysis compares the total 
      direct medical costs associated with VTE prophylaxis with enoxaparin and 
      unfractionated heparin (UFH). Hospital discharge and billing records were 
      extracted from the Premier Perspective database (January 2002-December 2006). The 
      primary outcome was the total direct medical costs for discharges that were at 
      risk of VTE and received enoxaparin or UFH. A total of 894,364 discharge records 
      met the study inclusion criteria, of which 39.4% received enoxaparin and 60.6% 
      received UFH. After adjustment for pre-defined covariates, mean total direct 
      medical costs per discharge for the UFH group were $6,443, $1,080 more than those 
      for the enoxaparin group ($5,363; P < .0001). In conclusion, enoxaparin 
      prophylaxis is a cost-saving therapy, when compared with UFH, for the prevention 
      of VTE in patients with a diverse range of medical conditions conferring VTE 
      risk.
FAU - Merli, Geno
AU  - Merli G
AD  - Jefferson Vascular Diseases Center, Jefferson Medical College, Thomas Jefferson 
      University Hospital, Suite 6250, Philadelphia, PA 19107, USA. 
      geno.merli@jefferson.edu
FAU - Ferrufino, Cheryl P
AU  - Ferrufino CP
FAU - Lin, Jay
AU  - Lin J
FAU - Hussein, Mohammed
AU  - Hussein M
FAU - Battleman, David
AU  - Battleman D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Thromb Thrombolysis
JT  - Journal of thrombosis and thrombolysis
JID - 9502018
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticoagulants/*administration & dosage/*economics
MH  - Costs and Cost Analysis
MH  - Databases, Factual
MH  - Enoxaparin/*administration & dosage/*economics
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Venous Thromboembolism/*economics/*prevention & control
EDAT- 2009/10/23 06:00
MHDA- 2010/08/14 06:00
CRDT- 2009/10/23 06:00
PHST- 2009/10/23 06:00 [entrez]
PHST- 2009/10/23 06:00 [pubmed]
PHST- 2010/08/14 06:00 [medline]
AID - 10.1007/s11239-009-0371-x [doi]
PST - ppublish
SO  - J Thromb Thrombolysis. 2010 May;29(4):449-58. doi: 10.1007/s11239-009-0371-x.